Metabolic Dysfunction-Associated Steatohepatitis
Oct 18, 2024
From NASH to MASH: Unraveling the Evolution and Future of Liver Disease Treatment
In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn't merely a rebranding; it signifies a profound recognition of the intricat...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
